An in-depth look to WAVERLEY PHARMA INC. operating, investing, and financing activities

5GZ free cash flow for Q1 24 is -76.73 k EUR. For 2023, 5GZ free cash flow was -698.02 k EUR and operating cash flow was -698.02 k EUR.